Viking Therapeutics, Inc. (VKTX) News
Filter VKTX News Items
VKTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VKTX News Highlights
- VKTX's 30 day story count now stands at 2.
- Over the past 4 days, the trend for VKTX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest VKTX News From Around the Web
Below are the latest news stories about VIKING THERAPEUTICS INC that investors may wish to consider to help them evaluate VKTX as an investment opportunity.
Better Growth Stock: Viking Therapeutics or Iovance Biotherapeutics?Both of these pharma stocks could be big winners. But one stock screens as a better buy from a risk standpoint. |
Why Viking Therapeutics Was Crushing It This WeekA multibillion-dollar deal in the healthcare industry helped lift the stock of a company, Viking Therapeutics (NASDAQ: VKTX), not directly involved in the transaction. As a result, according to data compiled by S&P Global Market Intelligence, Viking's share price was up by a whopping 39% week to date as of Friday before market open. The week kicked off with global pharmaceutical company Roche (OTC: RHHBY) announcing it signed an agreement essentially to acquire clinical-stage biotech Carmot Therapeutics. |
Obesity Drugs Have Multi-Billion-Dollar Market Potential, Says Oppenheimer — Here Are 2 Stocks to Take AdvantageA key to success in the stock market is a touch of foresight. Not quite precognition, but an ability to spot and put together clues and trends, to discern the ‘next big thing’ before it hits. This is true in every stock sector, but today we’ll focus on biotech. The biotech firms have famously high product lead times, paired with equally high overhead expenses; it’s a combination that would make them unlikely investments, except that when a drug is approved, it can turn into a blockbuster. Succes |
Viking Therapeutics, Inc. (NASDAQ:VKTX) is favoured by institutional owners who hold 74% of the companyKey Insights Significantly high institutional ownership implies Viking Therapeutics' stock price is sensitive to their... |
Viking Therapeutics Presents New Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at The Liver Meeting® 2023Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the presentation of new results from the ongoing Phase 2b clinical trial of VK2809, the company's novel liver-selective thyroid hormone receptor beta agonist, in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH). The latest findings from the VOYAGE study were featured in a late breaki |
Q3 2023 Ligand Pharmaceuticals Inc Earnings CallQ3 2023 Ligand Pharmaceuticals Inc Earnings Call |
1 Under-the-Radar Stock That Could Triple By 2030Naturally, several biotech giants will dominate this industry, the two most important (by some margin) being Novo Nordisk and Eli Lilly. While both stocks are well worth investing in, one smaller company in this space might have an even more substantial upside potential: Viking Therapeutics (NASDAQ: VKTX). Viking is developing another candidate, VK2735, as an obesity treatment. |
Viking Therapeutics to Participate at Upcoming Investor ConferencesViking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at several upcoming investor conferences. |
Viking Therapeutics, Inc. (NASDAQ:VKTX) Q3 2023 Earnings Call TranscriptViking Therapeutics, Inc. (NASDAQ:VKTX) Q3 2023 Earnings Call Transcript October 25, 2023 Viking Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.23 EPS, expectations were $-0.22. Operator: Welcome to the Viking Therapeutics Third Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Following management’s prepared remarks, we […] |
Q3 2023 Viking Therapeutics Inc Earnings CallQ3 2023 Viking Therapeutics Inc Earnings Call |